MDxHealth (NASDAQ:MDXH – Get Rating) is one of 45 publicly-traded companies in the "Medical laboratories" industry, but how does it contrast to its rivals? We will compare MDxHealth to similar companies based on the strength of its valuation, institutional ownership, dividends, profitability, risk, earnings and analyst recommendations.
Earnings and Valuation
This table compares MDxHealth and its rivals gross revenue, earnings per share and valuation.
Get MDxHealth alerts:| Gross Revenue | Net Income | Price/Earnings Ratio | |
| MDxHealth | $37.05 million | -$44.04 million | -1.37 |
| MDxHealth Competitors | $964.07 million | -$107.46 million | 4.34 |
MDxHealth's rivals have higher revenue, but lower earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
12.6% of MDxHealth shares are held by institutional investors. Comparatively, 47.0% of shares of all "Medical laboratories" companies are held by institutional investors. 16.4% of shares of all "Medical laboratories" companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings for MDxHealth and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MDxHealth | 0 | 0 | 3 | 0 | 3.00 |
| MDxHealth Competitors | 167 | 826 | 1723 | 32 | 2.59 |
MDxHealth currently has a consensus target price of $12.00, indicating a potential upside of 359.77%. As a group, "Medical laboratories" companies have a potential upside of 53.00%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than its rivals.
Risk & Volatility
MDxHealth has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, MDxHealth's rivals have a beta of 1.00, indicating that their average share price is 0% more volatile than the S&P 500.
Profitability
This table compares MDxHealth and its rivals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MDxHealth | -118.86% | -218.20% | -44.01% |
| MDxHealth Competitors | -1,181.51% | -78.19% | -28.91% |
Summary
MDxHealth rivals beat MDxHealth on 8 of the 13 factors compared.
About MDxHealth
(Get Rating)
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.